Open AccessThe potential of theragnostic 124I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma
Author(s) -
Nicole Luther,
Zhiping Zhou,
Pat Zanzonico,
N K Cheung,
John L. Humm,
Mark Edgar,
Mark M. Souweidane
Publication year - 2014
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/not298
Subject(s) - pons , toxicity , radioimmunotherapy , medicine , nuclear medicine , glioma , in vivo , dosimetry , monoclonal antibody , cancer research , antibody , biology , microbiology and biotechnology , immunology
Reasons for failure in prior human glioma convection-enhanced delivery (CED) clinical trials remain unclear. Concentration-dependent volume of distribution (Vd) measurement of CED-infused agents in the human brain is challenging and highlights a potential technical shortcoming. Activity of iodine isotope 124 ((124)I ) in tissue can be directly measured in vivo with high resolution via PET. With the potential therapeutic utility of radioimmunotherapy, we postulate (124)I conjugated to the antiglioma monoclonal antibody 8H9 may serve as a "theragnostic" agent delivered via CED to diffuse intrinsic pontine glioma.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom